The DT40 cell line has been used extensively to better understand the nature of immunoglobulin diversification in chickens, including the mechanism of GC (–). The cell line has also been used to develop chicken antibodies to novel targets using in vitro selection strategies (, ). We have inserted human V gene arrays into the chicken immunoglobulin loci of DT40. In principle, the human V genes in DT40 cells could be diversified in vitro to provide an unselected library of immunoglobulin sequences from which antigen-specific antibodies could be extracted. However, most therapeutic antibodies are derived from immunized animals producing affinity-matured, antigen-specific antibodies. In the current context, we have used DT40 cells to provide in vitro proof of concept that arrays of human-derived immunoglobulin gene sequences can be diversified by chicken B cells. Subsequently, these sequences will be introduced into chickens to provide genetically engineered animals that can be immunized to produce affinity-matured, antigen-specific antibodies with therapeutic potential. Thus, our purpose with DT40 is to determine whether targeted synthetic human V gene arrays can be used as a substrate for genetic diversification in chicken cells in a way that mirrors what is known regarding the native chicken immunoglobulin loci. Affirmative data in the DT40 culture system inspires confidence that the effort required on the arduous path to generating a genetically engineered chicken will be rewarded with a transgenic animal that performs as expected.
Next time keep your genetically engineered chicken to yourself
When placed in ultraviolet light, the beaks and feet of these genetically engineered chicken glow neon green, to help researchers tell them apart from the other birds. But glow-in-the-dark features aren't the traits these birds are being breed for, but rather the ability to help fight the spread of avian bird flu.
I bet those are just non-genetically engineered chicken wings..
The “Kanuma Chickens” represent the third genetically engineered animal that FDA has approved via its new animal drug authorities. The first such approval was for a goat that produces a human biologic in its milk, which was approved in 2009 (see our post on the Atryn Goats ). The second was the genetically engineered AquAdvantage Salmon, which FDA approved last month for use as a food-producing animal (see our post on the salmon approval ). The Kanuma Chickens are the second CVM approval for an animal engineered to produce a pharmaceutical product, and the first approval of a genetically engineered chicken.
and evolutionary studies on genetically engineered chicken lysozyme